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Considerable insight has been gained into the
etiopathogenesis of poststreptococcal glomerulonephritis
since the landmark theoretical construct of Clemens von
Pirquet postulated that disease-causing immune complexes
were responsible for the nephritis that followed scarlet fever.
Over the years, molecular mimicry between streptococcal
products and renal components, autoimmune reactivity and
several streptococcal antigens have been extensively studied.
Recent investigations assign a critical role to both in situ
formation and deposition of circulating immune complexes
that would trigger a variety of effector mechanisms.
Glomerular plasmin-binding activity of streptococcal
glyceraldehyde-3-phosphate-dehydrogenase may play a role
in nephritogenicity and streptococcal pyrogenic exotoxin B
and its zymogen precursor may be the long-sought
nephritogenic antigen.
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It has been known for a long time that scarlatina nephritis
appears as a rule in the third week. None of the hypothesis
thus far advanced is able to account satisfactorily for the fact
that nephritis occurs just at that time.
von Pirquet C. Allergy. Arch Int Med 7:259–288, 382–436,
1911.
Acute poststreptococcal glomerulonephritis (APSGN) is
an ancient and well-defined renal disease. Recent decades
have seen a reduction in the incidence of the disease
for reasons not entirely clear, but likely associated with
earlier recognition and effective treatment of streptococcal
infections. Nevertheless, epidemics and clusters of cases
continue to appear in several regions of the world and
sporadic cases of APSGN account for 21% (4.6–51.6%) of
children admitted to the hospital with acute renal failure in
developing countries.1
In the 18th century, it was recognized that ‘edematous
swelling with scanty, dark and at times totally suppressed
urine’ was a feared complication of the convalescent period
of scarlet fever,2 but it was Wells3 who, in 1812 published
a classic paper, actually delivered 6 years before to the Society
for the Improvement of Medical and Chirurgical Knowledge,
defining the limits of the latent period and the characteristics
of the edema, giving evidence that the urine contained
the ‘red matter’ as well as ‘the serum of the blood’ and
emphasized that this complication occurred more frequently
in siblings than in the general population. This communica-
tion preceded by more than 10 years the landmark
clinicopathological contributions of Richard Bright,4 which
established the connection between dropsy and coagulable
urine, and by more than six decades the finding of ‘glome-
rulitis’ in postscarlatinal nephritis5 and the report of Reichel6
that gave a clear description of the glomerular lesions in
a fatal cases of the disease subsequently expanded on by
Osman et al.7
Despite the fact that both the clinical features and the
renal pathology of the disease were well known, the reasons
for the association between this clearly non-infectious
(‘reactive’) complication of an infectious and, at that time,
epidemic disease remained elusive until the seminal work of
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Clemens von Pirquet.8 In 1903, von Pirquet, then a 29-year-
old pediatrics resident, purely on the basis of clinical
observations, postulated the existence of antibody-driven
pathogenic, rather than beneficial immune reactions that he
named allergy (‘altered reactivity’). Interestingly, in an
unusual method of claiming scientific priority for a concept,
he outlined his theory in a sealed letter sent to the Academy
of Sciences in Vienna that was only to be opened at his
request. This was in fact done in 1908 when the letter was
read in a session of the Academy.9
The term poststreptococcal glomerulonephritis became
usage following the demonstration that the b-hemolytic
streptococcus was the cause of scarlet fever, based on the
experimental work of Dick and Dick,10 the clinical work of
Dochez and Sherman11 and particularly reports in the first
half of the 20th century that identified cases of glomerulo-
nephritis following upper respiratory and skin infections
owing to streptococci. Among such reports, the work of
Little et al.,12 who identified bacteriologic and or serological
evidence of streptococcal infections in 109 of 116 consecutive
cases of acute glomerulonephritis and the association of
glomerulonephritis with pyodermitis and streptococcal
wound infections reported by Futcher,13 deserve specific
mention.
The next important theoretical concept was that of
‘nephritogenic’ streptococcal strains. This notion was advan-
ced initially by Seegal and Earle,14 who noted that rheumatic
fever and PSGN, both nonsuppurative complications of
streptococcal infection, did not coexist in the same patient,
differed in geographical location, in sex incidence (2:1
male:female predominance in PSGN), and propensity to
healing (PSGN) rather than to relapsing attacks (rheumatic
fever). Although recognizing that host differences ‘may play a
definite role’ in explaining these contrasting characteristics,
they championed a straightforward explanation, namely the
existence of hemolytic streptococcal strains that caused
rheumatic fever (hence rheumatogenic strains) and other
strains that caused glomerulonephritis (nephritogenic
strains). Subsequent investigations15–18 were considered to
validate this concept and laid the foundations for the
search for nephritogenic antigens in group A streptococcal
strains isolated from patients with nephritis. As reviewed
elsewhere,19 Rebecca Lancefield’s M types 1, 2, 4, 12, 18, and
25 were strains with nephritogenic potential usually reco-
vered from the upper respiratory tract whereas M types 49,
55, 57, and 60 were usually associated with impetigo-
associated nephritis.18 More recently, the production of a
lipoproteinase that makes serum opaque (opacity factor) has
been used to subdivide M proteins into class I (opacity factor
negative) corresponding to serotypes that cause rheumatic
fever and class II (opacity factor positive) that corresponds to
serotypes that cause pyoderma and acute glomerulonephri-
tis.19 Although these associations were the foundation of
much research, accumulated evidence (see below) has
demonstrated that M protein is not the decisive factor in
streptococcal nephritogenicity.
EXPERIMENTAL MODELS OF PSGN
Following the demonstration of the etiologic role of the
group A streptococcus in induction of acute nephritis, many
attempts were made to induce experimental glomerulone-
phritis in animals, including rabbits, rats, mice, and monkeys.
The major difficulty is clear: group A streptococci are
specific human pathogens. Injections of dead streptococci,
toxic extracellular products, and streptococcal vaccines, deep
and superficial infections produced by inoculations with
live bacteria, and implantation of diffusion chambers have
been tried by many authors in attempts to reproduce the
characteristics of PSGN seen in humans.20–24 In relation to
experimental infection, Reed and Matheson25 as well as
Becker and Murphy26 were able to induce albuminuria and
hematuria, and occasionally hypertension and azotemia.
Unfortunately, these careful and laborious investigations did
not consistently produce glomerulonephritis and did not
permit evaluation of putative nephritogenic antigens.
More recently, Nordstram et al.27 explored streptococcal
nephritogenicity in a series of elegant studies using steel cages
and osmotic pumps implanted subcutaneously in rabbits
and in mice. They found clinical and histological evidence
of nephritis when the cages were filled with nephritis-
associated bacterial isolates and subsequently implicated
streptokinase as a nephritogenic factor,28,29 these results are
discussed later.
IMMUNE COMPLEX DISEASE AND COMPLEMENT ACTIVATION
Immune complexes represent the ‘toxic bodies’ proposed to
be responsible for the symptoms by von Pirquet.8 Although
the identity of the nephritogenic antigen remained con-
troversial, general agreement existed in the 1960s and 1970s
with respect to the nephritogenic role of circulating immune
complexes because of similarities between PSGN and the
acute (‘one-shot’) serum sickness model.30,31
Glomerular trapping of immune complexes is facilitated
by various factors. Among these, appropriate size
(300–500 000 Da), antigen:antibody relationship (combining
ratios near equivalence), type of antibody (class and affinity
determine half-life in plasma and ability to activate
complement), and the efficiency of the reticuloendothelial
system in clearing the complexes are relevant.30–32
It was accepted that immune complexes of appropriate
size32 (300–500 000 Da), could deposit in the glomeruli,
activate the complement system and local coagulation
mechanisms, and induce glomerulonephritis. In acute serum
sickness, as in PSGN, there is a full recovery of the renal
lesions and a transient reduction in serum complement
levels.31,33 With respect to circulating immune complexes, as
many as 2/3 of PSGN patients had serum antigen–antibody
complexes,34 but these were also present in controls and in
patients with uncomplicated streptococcal infections.35
Furthermore, there was no correlation between the presence
or the amount of circulating immune complexes and the
clinical or pathological characteristics of the disease,36 so
these findings lacked clinical significance.
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The critical role played by an in situ immune reaction
resulting from antibody meeting free antigen deposited in the
glomeruli was suspected as early as 1976.37 This possibility
was emphasized by the difficulties of inducing glomerulone-
phritis and the near impossibility of inducing subepithelial
immune deposits (humps), which represent the prototype
lesion in PSGN,38,39 with preformed immune complexes.
Large amounts of preformed immune complexes may
produce glomerulonephritis but this is leukocyte-mediated,
and the localization of the immune deposits is largely
subendothelial. The landmark experiments of Vogt et al.,40
who showed that cationic antigens could be attracted to
and effortlessly penetrate the negatively charged glomerular
basement membrane to induce prominent subepithelial
electron-dense deposits and severe glomerulonephritis,
suggested that cationic streptococcal antigens might have
a role in acute PSGN. Obviously, charge alone does not
govern in immune complex deposition in the glomeruli,
as highlighted by the fact that patients with vasculitis and
myeloperoxidase (cationic):anti-myeloperoxidase immune
complexes have a pauci-immune glomerulonephritis.
Complement activation is a central feature in APSGN and
the alternate pathway is preferentially activated. New insights
into the activation of complement have been gained by the
demonstration that immunoglobulin (Ig)-binding proteins
in the streptococcal surface bind C4BP (a C4b-binding
protein), thereby interfering with the classical pathway of
complement activation.41,42 Relevant for a putative nephrito-
genic antigen (extracellular cysteine proteinase (streptococcal
pyrogenic exotoxin B, SpeB)) that will be discussed later,
Wei et al.43 have recently shown that complement regulatory
proteins (FH and FHL-1), used for immune evasion by
Streptococcus pyogenes, are bacterial surface proteins that may
be removed by SpeB, suggesting that this protease may
modulate FH and FHL-1 recruitment during infection.
Additional information on complement activation in
PSGN was provided by Ohsawa et al.44 who found that the
lectin pathway of complement activation may be activated in
PSGN, probably by the recognition of glucosamine residues
in the bacterial wall by the mannan-binding lectin-starter
molecule; however, recent evidence shows that individuals
deficient in mannan-binding lectin may still develop
glomerulonephritis45 and the participation of this pathway
of complement activation in PSGN remains a matter of
speculation.
CELLULAR IMMUNE MECHANISMS IN PSGN
The presence of immunocompetent cells in biopsies of PSGN
was recognized more than two decades ago. Macrophages and
T helper cells were shown to infiltrate the glomeruli in early
biopsies.46 Infiltration of mononuclear cells may be pro-
moted by chemotactic factors of the complement system, but
infiltration by immune cells is not correlated with comple-
ment deposition.
Overexpression of the intercellular adhesion molecule-1
and lymphocyte function-associated antigen-1 was seen in
glomeruli and tubulointerstitial regions in APSGN,47 and
Rastaldi et al.48 showed that the intensity of intraglomerular
and tubulointerstitial intercellular adhesion molecule-1
staining correlated with the intensity of macrophage infiltra-
tion in glomeruli and the interstitium, respectively. Further-
more, the number of intraglomerular leukocytes correlated
with proteinuria.
Increased circulating levels of IL-6, IL-8, tumor necrosis
factor-a, and monocyte chemotactic protein-1 have been
found in APSGN49,50 and a correlation between proteinuria
and urinary monocyte chemotactic protein-1 excretion has
been demonstrated.51
From the evidence listed above, it can be concluded that
infiltrating immune cells play a role in the development and
severity of the inflammatory glomerular damage in PSGN.
However, the lack of a suitable animal model makes it
difficult to explore the relative importance of cell-mediated
immune reactivity and the good prognosis of APSGN makes
it unnecessary to consider the use of immunosuppressive
drugs in uncomplicated cases of the disease.
STREPTOCOCCAL NEPHRITOGENICITY
We will now consider potential pathogenetic mechanisms in
PSGN, including molecular mimicry between streptococcal
fractions and renal structural constituents, autoimmune
reactivity (in particular anti-IgG activity), plasminogen/
plasmin binding by streptococcal surface proteins, and
finally, glomerular immune complex formation involving
streptococcal antigenic components (Table 1).
MOLECULAR MIMICRY
Several investigators have studied structural similarities
between soluble fractions of streptococci and components
of the human glomerulus as a possible cause of nephri-
togenicity. Kefalides et al.52 reported antibodies to laminin,
Table 1 | Streptococcal nephritogenicity
Molecular mimicry
Cross-reactivity of streptococcal products with laminin, collagen,
GBM etc.
Anti-Ig reactivity
Streptococcal neuraminidase
Streptococcal Ig-binding receptors
Streptococcal-related glomerular plasmin-binding activity
Streptokinase
zSpeB/SpeB
Enolase
NAPlr–GAPDH
Streptococcal nephritogenic antigens
M protein
Histone-like proteins
NAPlr–GAPDH
zSpeB/SpeB
GBM, glomerular basement membrane; GAPDH, glyceraldehyde-3-phosphate-
dehydrogenase; Ig, immunoglobulin; NAPLr, nephritis associated plasmin receptor;
SpeB, streptococcal pyrogenic exotoxin B; zSpeB, zymogen precursor of SpeB.
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collagen, and other molecules in the sera of patients with
PSGN. Several authors found shared antigenic determinants
between M12 streptococcal protein and glomerular basement
membrane,53–55 vimentin,56 and mesangial proteins,57 and
Kraus and Beachey58 found M protein epitopes of potential
renal autoimmune relevance.
However, there are little, if any, differences in the cross-
reactivity patterns of streptococci with rheumatogenic
potential compared with those with nephritogenic poten-
tial.59 An extensive review of the experiments reporting cross-
reactivity between mammalian tissues and streptococci by
Christensen et al.60 concluded that most of the preparations
used likely contained streptococcal Ig receptors or tissue IgG
Fc receptors or, in those studies where sera were involved,
anti-Igs; furthermore, they emphasized the near impossibility
to induce disease with injections of cross-reactive antigens.
AUTOIMMUNE REACTIVITY IN PSGN
The existence of autoimmune mechanisms triggered by
streptococci capable of causing nephritis was championed by
McIntosh et al.23,61,63,64 in the early 1970s. They showed that
cryoglobulins had a role in experimental nephritis induced by
type 12 streptococcus,23 that streptococcal neuraminidase
could eliminate the sialic acid of IgG, and that such autologous
desialized IgG was capable of inducing anti-IgG reactivity and
glomerular lesions.61 IgG-rheumatoid factor was subsequently
demonstrated in the serum of 32–43% of patients with PSGN
and IgM-rheumatoid factor in 15% of the patients,33,62
particularly in the first week of the disease.63 In addition,
anti-Ig deposits were demonstrated in the glomeruli of 19 of
22 biopsies64 and IgG with anti-IgG reactivity was eluted from
the kidneys of a fatal case of PSGN.65 More evidence of anti-
IgG activity was found with the skin-window technique, which
showed that patients with PSGN reacted to normal human
IgG with a lymphocytic infiltrate similar to the recognition
reaction observed in response to antigens to which the patient
had had previous exposure.66
Two mechanisms have been advanced to explain the
development of anti-IgG activity in PSGN: neuraminidase-
induced desialization of Ig and IgG-binding proteins in the
streptococcal wall. Although neuraminidase production was
reported in streptococci of M types 1, 4, and 12,67 there are
conflicting reports on its frequency among isolates.68–70 likely
owing to loss of neuraminidase production by bacteria after
repeated subculturing.69
Serum neuraminidase activity and free neuraminic (sialic)
acid levels were found in PSGN patients by us71 and others.72
Additional evidence in favor of a nephritogenic role for
neuraminidase was presented in experiments that showed
that desialized leukocytes have an affinity for the glomeruli73
and by the demonstration of glomerular-binding sites for
Arachys hypogea (peanut agglutinin), presumably identifying
free galactosamine radicals exposed by the loss of sialic acid
from deposited Igs74 and desialized leukocytes.75 The
association of APSGN and thrombotic microangiopathy in
a patient suggested a role of neuraminidase in the combined
clinical picture.76 Despite this evidence, it should be noted
that the capacity to produce neuraminidase is not a unique
characteristic of nephritogenic streptococci; in fact, rheuma-
togenic streptococci also produce this enzyme.68
Anti-Ig production could also be the result of Ig binding
to receptors in the streptococcal wall. Type II receptors in
groups A, C, and G streptococci have been demonstrated by
several authors.77–79 These receptors bind avidly to the Fc
fragment of IgG and anti-IgG antibodies are systematically
produced by the injections of group A streptococci cultured
in medium containing autologous serum.80 Anti-IgG activity
induced by streptococci with Ig-binding receptors is
associated with enhanced tissue deposition of IgG and
immune complexes in rabbits, causing inflammatory glo-
merular changes.81,82 Streptococcal receptors with affinity for
IgM have also been described.83,84
Ig-binding capacity by streptococcal components may
have additional nephritogenic relevance. Protein H, a surface
protein of S. pyogenes interacting with the constant Fc region
of IgG, is known to be released from the streptococcal surface
by cysteine proteinase (SpeB) produced by the bacteria. Berge
et al.85 have shown that addition of protein H to human
serum produces complement activation with dose-dependent
cleavage of C3. Protein H–IgG complexes released from the
streptococcal surface may then be relevant not only as
modulators of complement activation but also as inducers of
anti-IgG reactivity. The latter suggests a link between a
putative nephritogenic antigen (SpeB – see later) and anti-
IgG reactivity in PSGN.
In addition to anti-IgG, other autoimmune reactivity has
been found in patients with PSGN. DNA–anti-DNA com-
plexes86 and antineutrophil-cytoplasmic antibodies have also
been detected. The latter are present in as many as 2/3 of the
patients in whom there is azotemia and in 70% of the
patients that develop crescentic glomerulonephritis after
streptococcal infection.87
From the evidence listed above, it may be concluded that
autoimmune reactivity and, particularly, anti-IgG antibodies
in serum and in glomerular deposits are frequently present in
PSGN. As these autoimmune phenomena do not define a
specific clinical course of the disease, it is possible that they
represent epiphenomena; however, it is not unreasonable to
consider that in some patients, severe autoimmune reactivity
may modulate the course of PSGN.
NEPHRITOGENIC STREPTOCOCCAL ANTIGENS
The lack of a suitable animal model for PSGN made it
necessary to focus attention on selected streptococcal
fractions and their potential to deposit in the glomeruli
and cause injury. In parallel, studies were directed to detect
these putative antigens in renal biopsies of patients with
APSGN and the corresponding antibody response.
M PROTEINS
Several early investigations reported M proteins in human
renal biopsies,88–90 but the results were inconsistent.91,92 The
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discrepancies were attributed to impurities of the strepto-
coccal fractions used to produce the antisera and to variation
in the timing of the biopsy, but also free antigen unmasked by
antibody is more likely to be present in early biopsies.90,93
Experimentally, it could be shown that complexes of M
protein and fibrinogen could localize in the glomerulus94,95
and mild, self-limited renal lesions were induced by repeated
injections of M protein, either alone or in combination with
fibrinogen.96
In the following years, evidence against a primary role of
M protein accumulated. First is the fact that recurrence of
PSGN is extremely rare, if it occurs at all, which is compatible
with the notion of ubiquitous antigen(s) conferring long-
lasting immunity and conflicts with the mounting number of
putative nephritogenic M-proteins types that do not confer
lifetime immunity. In addition, Treser et al.97 showed that
convalescent sera, presumably containing antibody against
the specific nephritogen, could recognize free antigenic sites
in early biopsies, but this staining was not prevented by
preabsorbing the sera with M protein. Interestingly, attempts
to evaluate the specificity of IgG eluted from the kidney in a
fatal case of PSGN did not show anti-M type streptococcal
reactivity.65 Finally, in recent years, it has been shown that
not only group A streptococci have nephritogenic potential,
as Streptococcus zooepidemicus (group C), known to be the
cause of equine ‘strangles (fever, mucopurulent nasal
discharge, lymphadenitis, and submandibular abscesses)
and mastitis in cows, has been responsible for recent
epidemic outbreaks and clusters of cases of PSGN in different
parts of the world.98,99
STREPTOKINASE
In 1979, Villarreal et al.100 described a protein in nephrito-
genic streptococci that was present in glomerular deposits in
most biopsies from patients with APSGN and was recognized
by the majority of sera of patients with PSGN.101 Subsequent
experiments identified this protein as streptokinase102 and,
following this lead, Nordstrand et al.27 using the mouse
tissue-cage model induced glomerular lesions with strepto-
kinase-producing streptococci and showed that deletion of
the gene encoding a streptokinase variant associated with
nephritis resulted in loss of nephritogenicity.29 In addition,
they identified streptokinase in the glomeruli of some
infected mice by the immunogold silver-staining technique.28
However, production of this streptokinase variant was not
invariably associated with nephritis in the mouse cage
model29 and anti-streptokinase antibody titers do not offer
critical information on streptococcal infections associated
with nephritis.103,104 Furthermore, streptokinase alleles that
were thought to be present mainly in nephritogenic strains
are just as common in non-nephritogenic streptococci.105 In
subsequent experiments, the group that had originally
proposed streptokinase as a nephritigenic antigen concluded
that there was no unique reactivity to streptokinase in PSGN
patients and that there were no streptokinase deposits in
human renal biopsy material.106 Therefore, streptokinase has
been removed from the list of candidate nephritogenic
antigens in PSGN. Nevertheless, streptokinases are proteins
secreted by streptococci with the capacity to convert
plasminogen to plasmin107,108 and both Poon-King et al.109
and Nordstrom et al.27 suggested that binding of strepto-
kinase could convert plasminogen to active plasmin, which
could cause degradation of extracellular matrix proteins,
activation of matrix metalloproteinases, and local activation
of the complement and coagulation pathways. Plasmin-
initiated tissue injury could assist deposition of, and promote
further damage by immune complexes. This notion was
subsequently embraced by Yoshizawa et al.110,111 in their
studies on the streptococcal glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) plasmin receptor (see below). This
pathogenic mechanism may also be triggered by other
streptococcal antigens with the capacity to activate and bind
plasmin (see later). Interestingly, mouse plasminogen is not
activated by streptokinase,112 which would imply a different
mechanism for the streptokinase-induced nephritis observed
in the mouse cage model.
STREPTOCOCCAL HISTONE-LIKE PROTEINS
Bacterial histone-like proteins (HlpA) of streptococci may
contribute to the virulence of infections by promoting
monocytes/macrophages to synthesize and release proin-
flammatory cytokines.113 HlpA are highly cationic and
selective binding of HlpA to proteoglycans in the rabbit
glomerular basement membrane has been reported,114 and
this binding might initiate in situ immune complex
formation.115 The potential nephritogenicity of HlpA has
been suggested because it is released into the circulation by
group A streptococci in vivo and it elicits an antibody
response.116 To our knowledge, determination of anti-HlpA
antibodies in patients with poststreptococcal sequelae and
streptococcal histone localization in the glomeruli of PSGN
patients has not been reported, thus its role in PSGN is
speculative.
NEPHRITIS-ASSOCIATED STREPTOCOCCAL PLASMIN
RECEPTOR
Identification of nephritis-associated streptococcal plasmin
receptor (NAPlr) as a putative nephritogen is the culmina-
tion of a long series of studies initiated in the 1960s by Treser,
Lange, Yoshizawa.97,110 The current focus of investigations
is a plasmin-binding protein on the surface of nephritogenic
streptococci.117 These studies followed the identification of a
fraction obtained in the supernatant of pressure-disrupted
streptococci named endostreptosin118 or preabsorbing
antigen.119 Early biopsies of PSGN presented sites that stain
positive with fluorescein isothiocyanate-labeled Ig from con-
valescent sera presumably identifying free antigenic sites. The
preabsorbing antigen was so-named because it was shown to
preabsorb the staining capacity of convalescent sera. How-
ever, it was later shown that convalescent sera had anti-IgG
reactivity33,62 that could be responsible for the positive
stainings found in PSGN biopsies. Repeated injections of
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preabsorbing antigen in rabbits resulted in glomerular C3
staining and mild proliferative changes with minimal or no
proteinuria or hematuria.120 Recent reports deal with an
NAPlr of 43 kDa, initially identified by Winram and
Lottenberg,121 which is a glycolytic enzyme with glyceralde-
hyde-3-phosphate-dehydrogenase (GAPDH) activity.113
Streptococcal plasminogen-binding proteins may facilitate
bacterial invasion since, as mentioned earlier, surface-bound
plasmin activates both metalloproteinases and collagenases,
which can induce local inflammation.
Studies by Yoshizawa et al.104 showed that NAPlr activated
the alternate complement pathway, that high antibody titers
to NAPlr (as determined by Western blot in comparison with
normal controls) were present in 92% of PSGN patients and
60% of uncomplicated streptococcal infections remaining
elevated for at least 10 years, and that renal NAPlr deposits
were found in all renal biopsies of patients with APSGN
taken in the first 14 days of the disease. In a follow-up
investigation,111 the same authors demonstrated prominent
glomerular plasmin-like activity in patients who had APSGN
and in whom glomerular NAPlr was positive, whereas it was
absent or weak in patients who had APSGN and in whom
glomerular NAPlr was negative. The distribution of glomeru-
lar plasmin-like activity was identical to that of NAPlr.
Importantly, the distribution of the deposits of NAPlr did not
coincide with the distribution of complement or IgG
deposits111 and therefore the authors postulated that
nephritogenicity of NAPlr is related to its plasmin-binding
capacity, which was likely to facilitate immune complex
deposition.
Several questions remain to be answered in relation to
these detailed investigations. First is the possibility of cross-
reactivity with human GAPDH. This needs to be considered,
because the staining of certain structures, particularly
infiltrating leukocytes, in the biopsies presented by the
authors,104 is a regular feature in biopsies stained with anti-
human GAPDH (unpublished data from our laboratories).
In addition, a recent multicentric investigation revealed
different results; as evaluated by both enzyme-linked
immunosorbent assay and Western blot, anti-NAPlr anti-
bodies were a rare occurrence and glomerular deposition of
streptococcal NAPlr was infrequent in PSGN.122 One possible
reason for the contrasting observations in these studies is the
different genetic background of the patients in the cited
studies: the patients in the study of Batsford et al.122 had
many different genetic backgrounds, whereas the patients in
the studies by Yoshizawa et al.104 were drawn from a relatively
homogeneous Japanese population.
Also unanswered is the relationship between plasmin-
binding activity and nephritogenicity. It is intellectually
appealing to assign a pathogenic role to the capacity to bind
activated plasmin to the glomeruli and this mechanism could
be operating in relation to several streptococcal fractions, in
addition to NAPlr–GAPDH; for instance, streptokinase,
SpeB, and enolase. In fact, the latter has the strongest
plasmin-binding activity and a nephritogenic potential has
been suggested for a-enolase.123 Nevertheless, plasmin-
related nephritogenicity requires the participation of im-
mune complexes and the demonstration of the colocalization
of the putative antigen and the complement and Ig is a
dependable characteristic of such immune reactivity. The
different sites of glomerular localization for NAPlr and C3
and Ig104 would speak against its role as the nephritogenic
antigen.
SpeB/zSpeB
SpeB is a cationic cysteine proteinase that belongs to the
group of exotoxins (SpeA, SpeB, SpeC, and SpeD) produced
by pyogenic streptococci. One of these ‘erythrogenic’ toxins10
was found by Elliot in 1945124 to be an active proteinase of
28 kDa generated by proteolysis following reduction of an
extracellular zymogen precursor of B40 kDa produced by
group A streptococci. The proteinase (SpeB) and its
precursor (zSpeB) were subsequently identified by Gerlach
et al.125 and the crystal structure and integrin-binding
properties were defined by Kagawa et al.126
SpeB is present in all S. pyogenes isolates and is the
predominant extracellular protein, accounting for more than
90% of the total secreted protein. Patients with infections
with several M types seroconvert to SpeB, indicating that
the molecule is made in vivo in the course of strepto-
coccal infections.127 SpeB is a plasmin-binding receptor
protein128,129 that is capable of degrading human fibronectin,
activating a 66-kDa matrix metalloproteinase and of releasing
active kinins.130,131 zSPEB and SpeB are cationic with pKs of
8.2 and 9.3, respectively.
The possibility that SpeB/zSpeB could be a nephritogenic
antigen was raised after studies from Vogt et al.132 showed
that cationic antigens were present in the glomeruli in
APSGN. These glomerular deposits were later identified as
zymogen/streptococcal proteinase.40
Poon-King et al.109 in 1993 showed that streptococcal
nephritogenic strains produced a plasma-binding protein
identified as zSpeB and two simultaneous and independent
studies133,134 provided evidence for a role of SpeB and zSpeB
in APSGN. Cu et al.134 showed that 12 of 18 renal biopsies of
patients with PSGN had deposits of SpeB and high anti-SpeB
antibody levels were present in patients with PSGN, but not
in patients with uncomplicated streptococcal infections or in
patients with acute rheumatic fever. Parra et al.133 did a
multicentric study of 153 patients with APSGN, 23 patients
with uncomplicated streptococcal infections and 93 controls
in Venezuela, Chile, and Argentina and found that anti-zSpeB
titers of 1:800–1:3200 had a likelihood ratio (sensitivity/
1-specificity) for the detection of streptococcal infections
associated with glomerulonephritis of 2.0–44.2 and that
receiver operating characteristic curves showed that anti-
zSpeB titers were consistently superior to anti-streptolysin
O titers and anti-DNAase B titers.
In a more recent study, Batsford et al.122 evaluated NAPlr
and zSpeB/SpeB in biopsies and sera obtained from the
patients with PSGN in Venezuela, Chile, and Switzerland.
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They found SpeB deposits in 12 of 17 biopsies and circulating
anti-SpeB antibodies in 53 of 53 sera examined. In contrast,
circulating antibodies to NAPlr were detected in five of
47 sera and unequivocal glomerular deposits of NaPlr in
only one biopsy (borderline in 2). Importantly, these studies
showed colocalization of SpeB and complement and IgG in
the glomeruli (Figure 1b) and, in addition, they demon-
strated the existence of immunogold-labeled SpeB deposits
inside the electron-dense subepithelial deposits (‘humps’)
(Figure 1e) that are the histological hallmark of APSGN. As
discussed in earlier sections, other streptococcal antigens
have been localized in the glomeruli and previous studies had
shown intra-hump Ig;135 however, this is the first time that
streptococcal antigens have been demonstrated within this
particular lesion. Not surprisingly, this was attributed to
charge-facilitated penetration of SpeB, as is the case with
other cationic antigens that can induce similar electron-dense
subepithelial lesions experimentally.136,137
HOST FACTORS RESPONSIBLE FOR NEPHRITOGENICITY
Careful scrutiny of all the publications on PSGN fails to
identify properties of group A streptococci that are closely
correlated with the appearance of glomerulonephritis. For
example, the putative nephritogenic antigens SpeB/zSpeB
as well as NaPlr are found in virtually all S. pyogenes
isolates, including those strains associated with rheumatic
fever reviewed in Batsford et al.138 but only a minority of
patients develops nephritis. Particular properties of the
bacteria are rather essential but not sufficient for induction
of disease. Based on such observations, it has long been
accepted that host factors must play a major and decisive
role in determining who gets poststreptococcal nephritis.
In fact, as early as 1812, the ‘constitutional differences’
among families were assumed to be responsible for a familial
predisposition to PSGN.3 Subsequent studies showed that
20139–38%140 of siblings of patients with sporadic PSGN
developed clinical or subclinical nephritis. Nevertheless,
studies on human lymphocyte antigen antigen distribution
have failed to define a specific association with PSGN.141,142
Multiple factors are likely in play in the genetic predisposi-
tion to PSGN.
CONCLUDING REMARKS
A number of pathways by which streptococci could initiate
and perpetuate glomerular injury have been delineated
above. It seems unlikely that a single mechanism will be
responsible in all cases, although at this time we favor the
view that glomerular-immune complex formation is the
critical step in the initiation of the disease that as it evolves
recruits a variety of effector mechanisms. As PSGN develops
in a minority of the patients infected with nephritogenic
strains, it is clear that host factors are critical to determine
who gets and who does not get nephritis. What these factors
are is not clear at present.
It may be noted that nephritogenicity, understood as the
capacity for generating renal inflammation, is not the same as
nephritogenic antigen–antibody reactivity. The first may well
result from plasmin-binding characteristics, whereas the later
may involve colocalization of the putative antigen with
complement and Ig, as has been shown for streptococcal
SpeB (Figure 2). Further studies are required to elucidate the
participation of these elements in the pathogenesis of
poststreptococcal glomerulonephritis.
From the standpoint of diagnosis of nephritogenic
streptococcal infections, rising antibody titers to SpeB/
zSpeB or NaPlr represent the best evidence presently
available, but they are not available in clinical practice. Yet,
it is likely that they may be used to improve the etiologic
diagnosis of patients with acute nephritic syndrome in the
future.133
Clearly, in the 20th century we have gained great insight
into the pathogenesis of antigen–antibody reactions and
poststreptococcal nephritis, yet, to quote Wolfgang von
Goethe, ‘if you miss the first buttonhole you will not succeed
in buttoning up your coat’ (Wer das erste Knopfloch verfehlt,
kommt mit dem Zukno¨pfen nicht zu Rande. From ‘Maximen
und Reflektionen no. 900’) and it is fitting to give credit to
Clemens von Pirquet, a century after his sealed communica-
tion to the Vienna Academy of Sciences, for finding for us the
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Figure 1 | SpeB is colocalized with complement and Ig and shown
inside the subepithelial electron-dense deposits in APSGN. (a) A
light microphotograph of a glomerulus of APSGN (PAS staining,
original magnification  400) and (b) a merge microphotograph in
which zSpeB (fluorescein isothiocyanate-labeled, green) and C3
colocalization is shown in orange. The set of immune electron
microphotographs show a biopsy of APSGN in which the same
subepithelial electron-dense deposit (‘hump’) shows (c) C3, (d) IgG,
and (e) SpeB as immunogold-positive specs inside the hump. (f) a
composite in which the gold specs are substituted by colored spots is
shown. The microphotographs and electronmicrophotographs are
reproduced from Batsford et al.122
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elusive first buttonhole of this immune-mediated renal
disease.
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